Navigation Links
PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
Date:5/27/2009

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patients in hundreds of programs across 80 countries. PAREXEL will be marking this milestone during the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 - June 2, 2009 in Orlando, Florida. PAREXEL's hematology and oncology experts will be available during the ASCO meeting at Booth #1980 to discuss their capabilities to support the successful development of novel cancer treatments.

"Significant advances in targeted therapies for cancer have generated more competition for patient populations. To meet industry demand for conducting cancer trials across a broad range of indications, PAREXEL continues to leverage our global footprint and ability to manage complex programs on a worldwide scale to help biopharmaceutical companies access diverse patient populations, navigate regulatory issues, and identify effective investigators," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL International.

"With approximately 10 million people diagnosed with cancer each year worldwide, PAREXEL works with biopharmaceutical companies toward the goals of improving the development success rate for oncology drugs and getting treatments to patients sooner," said Denis R. Miller, M.D., Senior Medical Director, Clinical Research Services, PAREXEL. "Our global team of hematology and oncology experts helps clients advance important innovations through our understanding of unmet medical needs, the standards of available cancer care worldwide, and how new anticancer agents will be positioned in the treatment of patients, from th
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
6. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
7. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
8. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
9. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
10. Genmab Reaches Milestone in Ofatumumab Collaboration
11. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- Following the reintroduction of the Comprehensive Addiction ... a report today urging policymakers to take steps ... through more effective use of medication-assisted treatment (MAT).  ... Expanding Access to Medication-Assisted Treatment to Address the ... and economic advantages of medication-assisted treatment along with ...
(Date:3/4/2015)... , March 4, 2015  Heska Corporation (Nasdaq: ... Invites You to Join Its Fourth Quarter and Year ... 5, 2015 @ 9:00 a.m. (MST) / 11:00 a.m. ... End 2014 Earnings Call link on the front page ... on to the web at the address above.  Alternatively, ...
(Date:3/4/2015)... March 4, 2015   InspireMD, Inc.  ("InspireMD" or ... protection systems ("EPS"), today announced that it has entered ... 34 million shares of common stock and warrants to ... stock in a public offering.  The common stock will ... per share, and each purchaser will receive a warrant ...
Breaking Medicine Technology:Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2InspireMD Announces Public Offering for Approximately $13.5 Million 2InspireMD Announces Public Offering for Approximately $13.5 Million 3InspireMD Announces Public Offering for Approximately $13.5 Million 4
... Jan. 3, 2012  theVisualMD, www.thevisualmd.com , the world,s leading ... initiative, The 9 Visual Rules of Wellness. Quest Diagnostics (NYSE: ... testing, information and services, is the official sponsor of the ... 9 Visual Rules of Wellness aim to bring readers a ...
...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) and Eisai ... the Complete Response Letter (CRL) issued by the US Food ... Drug Application (NDA). Lorcaserin is intended for weight management, including ... are obese (Body Mass Index, or BMI, >30) or patients ...
Cached Medicine Technology:theVisualMD Launches a Revolutionary New Visual Path to Wellness 2theVisualMD Launches a Revolutionary New Visual Path to Wellness 3theVisualMD Launches a Revolutionary New Visual Path to Wellness 4Arena Submits Response to FDA Complete Response Letter for Lorcaserin 2Arena Submits Response to FDA Complete Response Letter for Lorcaserin 3Arena Submits Response to FDA Complete Response Letter for Lorcaserin 4Arena Submits Response to FDA Complete Response Letter for Lorcaserin 5Arena Submits Response to FDA Complete Response Letter for Lorcaserin 6
(Date:3/4/2015)... 04, 2015 With the growing influence of ... of our teens and young adults, combined with the increasingly ... confusing to try to keep up with what kids are ... trend is replaced on a daily basis. , The same ... the slang that is used to discreetly talk about them, ...
(Date:3/4/2015)... 04, 2015 More than a year ... potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), ... it will now require manufacturers to warn patients that ... heart attacks and strokes. In a Drug Safety ... stated that it was requiring testosterone manufacturers to update ...
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 2015 The print component of “Organic ... Francisco Chronicle with a circulation of approximately 173,000 copies ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... is composed of heat-dried microbes that have digested the ...
(Date:3/4/2015)... Atlanta, Georgia (PRWEB) March 04, 2015 ... Georgia, part of the School of Public Health at ... , The funds were awarded by Georgia’s Division of ... contract to support the DFCS Call Center. , ... child maltreatment by providing information and referral services that ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... adults of industrialized countries is approximately 10% and is ... is scarce. , A research article published ... Gastroenterology addresses this problem. The team lead by Dr. ... Canada, has reviewed the rate of gallstone disease and ...
... means of microsatellite markers has become an effective way ... candidate tumor suppressor genes. In a previous study, it ... frequencies, which indicated that the region might harbor the ... contained so many genes that it was inconvenient to ...
... Intraductal papillary neoplasm of the bile duct (IPN-B) is ... is a new definition of a tumor with papillary ... authors reported a case of IPN-B with interesting histopathological ... the diagnosis of bile duct dilatation due to the ...
... ARNA ) today announced it will report first ... on Wednesday, May,7, 2008. That same afternoon, Jack Lief, ... Arena,s Vice President, Finance,and Chief Financial Officer, will host ... Pacific Time) to discuss the first quarter 2008,financial results ...
... 30 The following is an,editorial from The Wall ... Committee:, [J]ohn McCain delivered another speech yesterday on ... could lead to some of the most,constructive changes to ... for his candidacy if Mr. McCain is making space ...
... FRAZER, Pa., April 30 Cephalon, Inc. (Nasdaq:,CEPH) ... Executive Vice,President and General Counsel. In this position, ... company, including those relating to commercial,and financial transactions, ... directly to Chairman and CEO, Frank,Baldino Jr., Ph.D., ...
Cached Medicine News:Health News:A patient who was diagnosed as IPN-B without hepatolithiasis? 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 3Health News:RNC: McCain's Progress 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 3
AnkleWALKER™ Shorter uprights and circumferential plastic shell inhibit foot and ankle motion. Designed to provide comfortable stability for acute ankle sprains, soft tissue injuries, stress an...
... The FoamWalker is a cost-effective walking ... support. It has a lightweight, durable, semi-rigid ... protection. The shell's rocker sole helps reduce ... two aircells for compression and support at ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... of controlled compression and cold, the Calf ... anatomically designed cuff provides complete calf coverage ... as a single cuff, or with a ... disk). The Cooler is available separately and ...
Medicine Products: